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Abstract
Objective: Cholesterol changes have been described in prion-cell models and in experimental rodent scrapie; yet,
the pattern of this association is still controversial.
Methods: To shed light on the matter, we analysed and compared cholesterol variations in ScN2a cells and in
brains of Scrapie-infected C57Bl/6 mice, using two different methods: a fluorimetric-enzymatic cholesterol assay,
and high performance liquid chromatography-mass spectroscopy (HPLC-MS).
Results: Compared to uninfected controls, similar cholesterol metabolism anomalies were observed in infected
cells and brains by both methods; however, only HPLC-MS revealed statistically significant cholesterol variations,
particularly in the cholesteryl esters (CE) fraction. HPLC-MS analyses also revealed different fatty acid composition of
the CE fraction in cells and brains. In N2a cells, their profile reflected that of serum, while in normal brains
cholesteryl-linoleate only was found at detectable levels. Following prion infection, most CE species were increased
in the CE pool of ScN2a cells, whereas a conspicuous amount of cholesteryl-arachidonate only was found to
contribute to the cerebral increase of CE. Of interest, oral pravastatin administration to Scrapie-infected mice, was
associated with a significant reduction of cerebral free cholesterol (FC) along with a concomitant further increase
of the CE pool, which included increased amounts of both cholesteryl-linoleate and cholesteryl-arachidonate.
Conclusion: Although mechanistic studies are needed to establish the pathophysiological relevance of changes in
cerebral CE concentrations, to the best of our knowledge this is the first report to provide evidence of increased
cholesterol esterification in brains of prion-infected mice, untreated and treated with pravastatin.
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Introduction
It is now accepted that modifications of cholesterol con-
centrations are linked to prion infection/replication
[1-4]; yet, no general agreement on the precise prion-
associated cholesterol concentration changes, as well as
on the relevance of cholesterol-lowering drugs in the
control of prion diseases, has been reached. In vitro,
some studies produced evidence that cholesterol deple-
tion abolishes prion protein (PrP)-raft association, pro-
motes PrP accumulation, and increases substantially its
misfolding into the pathologic scrapie-prion protein iso-
form (PrPSc) [5,6]. On the other hand, although the
majority of in vivo studies failed to link statins’ prophy-
lactic effect to a reduction of the bulk of cerebral cho-
lesterol [7-12], the lowering of cholesterol with statins
has been reported to inhibit PrPSc generation in cell-
based prion models [13,14]. More than just changes in
cholesterol contents, prion infection seems to be accom-
panied by a general derangement of cholesterol homeo-
static mechanisms [15,16], possibly triggered by prion
itself [4]. In our previous studies, increased levels of free
cholesterol (FC) and of the cholesterol fraction esterified
with free fatty acids (CE) were the main modifications
observed. In prion-infected ScN2a cells, a number of
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by affecting steps of cholesterol metabolism/trafficking
other than biosynthesis, were associated with a reduc-
tion of the CE pool and selective anti-prion activity
[17]. Furthermore, selected combinations of these cho-
lesterol-modulating drugs produced strong synergistic
anti-prion effects, apparently by restoring cholesterol
homeostasis [18]. Somewhat contradictory to our find-
ings, however, other research groups reported that the
increased content of FC in prion-infected neuronal cell
lines was associated with a reduced content of CE
[19,20]. Since the understanding of the mechanism(s)
that regulate the structural conversion of PrP into
pathogenic isoform(s) remain a fundamental target also
for the development of novel therapeutic approaches, it
is crucial to elucidate alterations in cholesterol meta-
bolism associated with prioni n f e c t i o n .I na d d i t i o nt o
discrepancies due to the different prion models
employed to study such a complex relationship, the
use of various methods for cholesterol measurements
may also have contributed to some of the present con-
flicting findings. In order to clarify these inconsistent
results, qualitative and quantitative cholesterol varia-
tions following Scrapie infection were analysed and
compared in brains of C57BL/6 mice, untreated and
treated with pravastatin (PRV), as well as in N2a cell
lines. Two methods were used: fluorimetric-enzymatic
Amplex Red cholesterol assay, and high performance
liquid chromatography with mass spectrometry
(HPLC-MS).
Materials and methods
Chemicals
Chloroform, methanol, N-heptane, di-isopropyl ether,
formic acid, acetonitrile, and iodine bisublimate were
purchased from Carlo Erba (Italy). Pravastatin (PRV)
sodium salt was kindly provided by Bristol-Myers
Squibb.
Cell lines
The mouse neuroblastoma N2a cell line and a sub-line
persistently infected with the mouse-adapted 22L-strain
of scrapie (ScN2a cells), were a generous gift of Byron
Caughey, Rocky Mountain Laboratories, NIAID-NIH,
Hamilton MT, USA. Cell lines were grown and main-
tained at 37°C and 5% CO2 in OptiMEM supplemented
with 10% bovine serum (Gibco-Invitrogen, Italy), 2 mM
L-glutamine, 50 U/ml penicillin G sodium, and 50 μg/
ml streptomycin sulphate (Gibco-Invitrogen, Italy), and
splitted every 3 to 4 days. Cell lines were replaced every
three months with freshly towed cells from liquid nitro-
gen. All experiments were carried out in exponentially
growing cells harvested as monolayers reached sub-con-
fluence (80-90%).
Mice
C57BL/6 mice were scrapie-infected and PRV-treated as
previously reported [21]. Briefly, one-month-old female
C57BL/6 mice (Charles River) weighing 18-20 g, were
inoculated intracerebrally (i.c.) in the left hemisphere
with 1% (w/v) brain homogenate prepared from termin-
ally ill, strain 139A scrapie-infected mice, and assigned
randomly to the untreated (n = 4) or the PRV-treated (n
= 4) group. Five mice were mock-inoculated (control
group, n = 5). PRV (mouse oral LD50, 8939 mg kg
-1)
was administered in the drinking water at a dose of 200
mg (kg body weight)
-1 day
-1 from the time of scrapie
inoculation. Mice were fed ad libitum with standard
chow diet. Water consumption was monitored twice
weekly and drug concentration was adjusted as required.
Control and untreated animals received water without
PRV. Terminally ill mice were killed by cervical disloca-
tion under CO2 narcosis. Brains were collected, divided
into the two hemispheres, and kept at -80°C. Hemi-
brains were thawed, weighed, and homogenized in nine
volumes (10% w/v) of phosphate-buffered saline (PBS,
Invitrogen) and 0,1% Triton X-100 by sonication pulses
(Vibra Cell, Sonics & Materials Inc., Newtown, CT) on
ice, then boiled for 15 min to inactivate endogenous cel-
lular cholesterol esterase. The resulting 10% homogenate
was stored at - 80°C until lipid extraction. Mice, indivi-
dually identified by a passive integrated transponder,
were treated according to Legislative Decree 116/92
guidelines. Animal welfare was routinely checked by
veterinarians from the Service for Biotechnology and
Animal Welfare of the Istituto Superiore di Sanità. The
research protocol has been approved by the Service for
Biotechnology and Animal Welfare of the Istituto
Superiore di Sanità and authorized by the Italian Minis-
try of Health, according to Legislative Decree 116/92
(Decreto Legislativo, 1992), which has implemented in
Italy the European Directive 86/609/EEC (Council of the
European Communities, 1986) on laboratory animal
protection.
Lipid Extraction from cell cultures
N2a and ScN2a cells were seeded at density of 1 ×
10
5cells/ml in T-75 flasks. After four day incubation at
37°C in a humidified 5% CO2 atmosphere, sub-conflu-
ent cultures were trypsinized and washed twice in sterile
PBS to eliminate residual growth medium. Cells were
resuspended in PBS, counted in a haemocytometer, and
viable cells divided into three aliquots. One aliquot of 1
×1 0
6 cells was used for protein determination by the
bicinchoninic acid protein assay (Sigma). The other two
aliquots were subjected to lipid extraction by the Folch
method [22]. Total lipid extracts were dried in an eva-
porator and re-suspended in methanol for HPLC-MS
analysis, or in Reaction buffer for Amplex Red
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extracts from a total of 30-40 × 10
6 cells. Amplex Red
determinations were performed on extracts from a total
of 4-5 × 10
6 cells.
Lipid Extraction from brain homogenates
Lipids were extracted from brain homogenates by the
Folch method [22]. In brief, brain homogenates were
mixed with chloroform-methanol (2:1 v/v). Vitamin E
was added as antioxidants to prevent lipid degradation
during analysis. After 1 hour incubation in the dark,
water was added (Clor/MeOH/H2O, 2:1:1 v/v/v) and
samples were incubated for an additional hour in the
dark. Samples were centrifuged at 1500 rpm for 1 hour
at room temperature, then the lipid-containing organic
phase was recovered. Total lipid extracts were dried in
an evaporator and re-suspended in methanol for HPLC/
MS analysis.
HPLC-MS cholesterol analysis
Separation of free cholesterol and cholesteryl esters was
carried out as described [23] with an Agilent 1100
HPLC system (Agilent, Palo Alto, CA) equipped with a
diode array and mass spectrometer detectors in line. A
C-18 Inertsil 5 ODS-2 Chrompack column (Chrompack
International BV, Middleburg, the Netherlands), 5 μm
particle size, 150. 4.6 mm was used. FC and CEs were
detected at 200 nm. Spectra (195-315 nm) of the elute
were obtained every 1.28 s, and were electronically
stored. These spectra were taken to confirm the identifi-
cation of the HPLC peaks. MS analysis was performed
using a single quadrupole mass spectrometer (Agilent,
Palo Alto, CA) equipped with an atmospheric Pressure
chemical ionization source. Each sample was triplicated
in the assays and at least three independent experiments
were performed.
Amplex Red cholesterol assay
Cholesterol content in cell and brain extracts was evalu-
ated by the Amplex Red Cholesterol Assay kit (Invitro-
gen) according to the manufacturer’s instructions.
Briefly, mouse brain and cell extracts were diluted 1:10
with 1× cholesterol reaction buffer (0.1 M potassium
phosphate, pH 7.4, 0.05 M NaCl, 5 mM cholic acid,
0.1% Triton X-100). Fifty microliters of 150 μM Amplex
Red reagent (1 U/ml horseradish peroxidase, 1 U/ml
cholesterol oxidase, and 1 U/ml cholesterol esterase)
were added to 50 μL sample in 96 well plates. After 60-
min incubation at 37°C in the dark, sample fluorescence
was measured using a microplate reader (Victor 3V
1420 Multilabel Counter, Perkin Elmer) at 530/25 nm
excitation, and 590/35 nm emission wavelengths. The
total cholesterol (TC) content was determined by mea-
suring the cholesterol concentration following digestion
with cholesterol esterase. To measure FC, cholesterol
esterase was omitted from the assay. Each sample was
triplicated in the assay and at least three independent
experiments were performed. Values obtained from a
cholesterol standard curve were normalized to 10
6cells
(N2a and ScN2a cells) or to g of tissue (brains).
Statistical analysis
All statistical comparisons were calculated using a two-
way, unpaired Student’s t-test. Statistical comparisons
among groups were also made by using a one-way
ANOVA, and where appropriate a post hoc Bonferroni
test. Statistical significance was assigned to p <0 . 0 5 .A l l
values are expressed as mean values ± standard devia-
tion (SD).
Results
Amplex Red vs. HPLC-MS cholesterol analyses in N2a cell
and C57Bl/6 mouse prion-models
Cholesterol measurements by Amplex Red showed a sig-
nificant increase in the FC content (p = 0.015) in ScN2a
cells compared to uninfected N2a cultures. Despite a
tendency to increase, total cholesterol (TC) and CE
levels did not significantly differ between infected and
uninfected cells (p =0 . 3 6 4a n dp = 0.664, respectively)
when determined by this method (table 1). By contrast,
HPLC-MS analysis showed that TC, FC and CE levels
were all significantly increased (p ≤ 0.006) in the ScN2a
cell extracts (table 1).
Given that lipid variation in N2a cell cultures may be
influenced by the serum in the culture medium, TC, FC,
and CE levels were also determined by the two methods
in brains of uninfected and terminally ill scrapie-infected
C57Bl/6 mice, untreated or treated with PRV (200 mg/
kg bw/day). Again, TC, FC and CE levels determined by
Table 1 Amplex Red vs. HPLC-MS cholesterol composition
in N2a and ScN2a cells.
Method Cell
lines
nmol/10
6 cells CE/TC
%
TC FC CE
Amplex
Red
N2a 80.11 ± 4.18 77.52 ± 0.38 2.59 ± 1.92 3.23
ScN2a 83.60 ± 4.18 79.80 ±
0.88*
3.81 ± 4.08 4.55
p = 0.364 p = 0.015 p = 0.664
HPLC-MS N2a 135.36 ±
13.59
98.38 ± 9.75 36.98 ±
4.01
27.0
ScN2a 200.37 ±
8.27*
146.54 ±
4.76*
53.83 ±
3.60*
26.8
p = 0.002 p = 0.002 p = 0.006
Total (TC), free (FC) and esterified (CE) cholesterol in uninfected (N2a) and
persistently prion-infected (ScN2a) cell extracts. Values represent the mean ±
SD of triplicate determinations and are representative of at least three
independent trials. *Statistical significance by unpaired Student’s t-test.
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and scrapie-infected brains (p > 0.3) (table 2). Instead,
when mouse brain extracts were subjected to HPLC-MS
analysis, the increase of cerebral CE in the scrapie-
affected group were highly significant (p = 0.008). In
addition, consistent with CE/TC percentages commonly
found in tumour cell lines and normal brains [24], direct
measurements by HPLC-MS revealed approximately
27% CE in uninfected N2a cells, and approximately 10%
CE in normal mouse brains (table 1 and 2). In contrast,
Amplex Red measurements underestimated percentages
of CE/TC, both in cells (< 5%) and brains (< 1%). The
HPLC-MS data also allowed us to show that, compared
to normal brains, CE/CT percentages significantly
increased (p = 0.029) in brains of the scrapie-affected
mouse group (from 9.2% to 12.3%), while they did not
vary in N2a and ScN2a cells (27.0% vs. 26.8%, respec-
tively) (tables 1 and 2).
According to our previous study [21], oral long-term
and high-dose PRV-treatment of scrapie-infected mice
confirmed a moderate prophylactic effect (data not
shown). As would be expected for an inhibitor of cho-
lesterol biosynthesis, a consistent reduction of FC was
observed in brains of PRV-treated vs. untreated Scrapie-
infected mice (table 3). Once again, it must be empha-
sized that statistically significant FC differences between
the drug-treated and the untreated group of infected
mice were revealed by HPLC-MS analyses (p =0 . 0 2 6 ) ,
but not by Amplex Red (p = 0.432). Unexpectedly, in
the PRV-treated scrapie-affected group, CE appeared to
be further increased (table 3). Statistical analysis per-
formed by using one-way ANOVA test showed signifi-
cant differences in FC and CE (p = 0.047 for FC, and p
= 0.001 for CE) among the three experimental groups, i.
e., uninfected, scrapie-infected, and scrapie-infected
PRV-treated. Of note, the opposite change in the con-
tent of FC, reduced, and CE, increased, by this drug
may explain why statistically significant variations in
cholesterol levels between untreated and PRV-treated
scrapie-infected mice have not previously been revealed
[10].
Fatty acid composition of CE in uninfected and prion-
infected N2a cell and C57BL/6 brain extracts
The HPLC-MS lipid analyses allowed us to identify and
measure various CEs based on the fatty acid (FA) esteri-
fied to cholesterol in our prion-models (Figure 1a and
1b). In uninfected N2a cells, the FA esterified to choles-
terol, from most to least abundant, were: oleic (C18:1) >
arachidonic (C20:4) > linoleic (C18:2) > miristic (C14:0)
> docosahexaenoic (C22:6) > a-linolenic (C18:3) > pal-
mithic (C16:0) (Figure 1a). With the exception of CE
20:4, all CE species quantitatively increased in ScN2a
cells; with C16:0, C18:1, and C22:6 being the most ele-
vated (Figure 1a). With respect to total CE, however,
higher proportions of C16:0, lower proportions of C20:4,
Table 2 Amplex Red vs. HPLC-MS cholesterol compositions in brains of uninfected and Scrapie-infected C57BL/6 mice.
Method Mouse brains μ mol/g tissue CE/TC %
TC FC CE
Amplex Red Uninfected 276.38 ± 11.78 275.24 ± 14.44 1.14 ± 1.24 0.41
Scrapie-infected 283.48 ± 8.74 282.24 ± 9.88 1.24 ± 1.59 0.43
p = 0.351 p = 0.438 p = 0.918
HPLC-MS Uninfected 124.35 ± 29.61 112.87 ± 17.37 11.48 ± 3.26 9.23
Scrapie-infected 156.58 ± 25.46 137.24 ± 16.70 19.33 ± 3.20* 12.34
p = 0.129 p = 0.071 p = 0.008
Total (TC), free (FC) and esterified (CE) cholesterol in brain extracts of uninfected (n = 5) and 139A-scrapie infected (n = 4) mice. Values represent the mean ± SD
of triplicate determinations and are representative of at least three independent trials. *Statistical significance by unpaired Student’s t-test.
Table 3 Amplex Red vs. HPLC-MS cholesterol compositions in brains of untreated and pravastatin-treated Scrapie-
infected C57BL/6 mice.
Method Scrapie-infected mouse brains μ mol/g tissue CE/TC %
TC FC CE
Amplex Red Untreated 283.48 ± 8.74 282.24 ± 9.88 1.24 ± 1.59 0.43
PRV-treated 279.12 ± 6.84 276.68 ± 8.74 2.44 ± 1.27 0.87
p = 0.462 p = 0.432 p = 0.283
HPLC-MS Untreated 156.58 ± 25.46 137.24 ± 16.70 19.33 ± 3.20 12.34
PRV-treated 134.17 ± 27.74 106.03 ± 13.46* 28.14 ± 6.62* 20.97
p = 0.247 p = 0.026 p = 0.05
Total (TC), free (FC) and esterified (CE) cholesterol in brain extracts of 139A-scrapie infected (n = 4), and of 139A-scrapie-infected C57Bl/6 mice treated with
pravastatin (PRV, 200 mg/kg b.w.). Values represent the mean ± SD of triplicate determinations and are representative of at least three independent. *Statistical
significance by unpaired Student’s t-test.
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C22:6 and C18:1 were observed in ScN2a compared to
N2a cells (Figure 1b).
Analyses of mouse brains showed an entirely different
CE composition (Figure 2a and 2b). The only CE identi-
fied in uninfected brains was CE 18:2. In scrapie-affected
brains, despite a significant increase in the CE fraction,
the level of CE 18:2 did not vary. Furthermore, a consis-
tent amount of CE 20:4 was detected. Interestingly, an
increase of both CE 18:2 and CE 20:4 appeared to char-
acterize the CE pool of PRV-treated scrapie-affected
brain extracts. The ANOVA test showed a highly signifi-
cant variation of C20:4 (p = 0.001) among the three
experimental groups, i.e. uninfected, scrapie-infected,
and PRV-treated scrapie-infected brains.
Discussion
In the current study, qualitative and quantitative lipid
analyses by HPLC-MS revealed multiple anomalies asso-
ciated with prion infection both in ScN2a cell cultures
and scrapie-affected C57Bl/6 mouse brains, mainly con-
sisting in abnormal accumulation of CE. These results
are in agreement with our previous findings [17,18], as
well as with those of a recent systems biology study
showing that the SOAT1 gene, encoding for the enzyme
(i.e. ACAT1) responsible for cholesterol esterification, is
  A B
Figure 1 HPLC-MS composition of fatty acids esterified to cholesterol in N2a and ScN2a cells. A) concentration of oleic (C18:1),
arachidonic (C20:4), linoleic (C18:2), miristic (C14:0), docosahexaenoic (C22:6), a-linolenic (C18:3), palmithic (C16:0) acid expressed in nanomoles/
10
6 N2a (uninfected) and ScN2a (prion-infected) cells. Values represent the mean ± SD of triplicate determinations and are representative of at
least three independent trials; B) each fatty acid as percentage of total cholesteryl esters (CE).
  A B
Figure 2 HPLC-MS composition of fatty acids esterified to cholesterol in brain extracts of uninfected, scrapie-infected, and scrapie-
infected PRV-treated C57BL/6 mice. A) concentration of linoleic (C18:2) and arachidonic (C20:4) acid expressed in micromoles/g of brain
tissue. Values represent the mean ± SD of triplicate determinations and are representative of at least three independent trials; B) each fatty acid
as percentage of total cholesteryl esters (CE). Variation of C20:4 among groups, i.e. uninfected, Scrapie-infected, and PRV-treated Scrapie-infected,
is statistically significant by ANOVA (p = 0.001).
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lated in the brain of scrapie-infected mice [25]. To date,
few studies have tried to dissect variations in intracellu-
lar FC versus CE pools [reviewed in 16], and no univo-
cal hypothesis yet exists on the increase of cytoplasmic
CE in prion-infected cells. As a matter of fact, some
authors using the fluorimetric-enzymatic cholesterol
assay Amplex Red reported that prion-infected neuronal
cell lines are characterized by a reduced content of CE
[19,20]. In our hands, however, even the Amplex Red
cholesterol measurements showed a higher, though not
statistically significant, CE content in ScN2a vs. N2a
cells. Mixed results may be accounted for by the fact
that Amplex Red directly measures only the TC and FC,
while the CE fraction is indirectly calculated by subtrac-
tion of FC from TC. Given that the percentage of CE in
TC is known to be always markedly low (between 10%
and 30% depending on the type of tissue) [24], the
experimental error using the Amplex Red method can,
in fact, become substantial [26]. Actually, we found that
CE levels calculated by Amplex Red were up to 90%
lower than those obtained by HPLC-MS, both in N2a
cells and mouse brains. Therefore, enzymatic assays
seem suitable for the rapid analysis of samples high in
cholesterol content (i.e. plasma), but less appropriate to
ascertain cholesterol concentration changes in other
types of samples, especially in those cells and tissues
where CE levels are particularly low. Also, it has to be
pointed out that, with respect to TC and FC content,
even though Amplex Red showed higher levels in all
prion-infected samples compared to uninfected controls,
only HPLC-MS data showed statistically significant dif-
ferences. Given that HPLC-MS identifies and quantifies
t h ed i f f e r e n tC Es p e c i e s ,w ew e r ea l s oa b l et od e m o n -
strate that an entirely different composition of FA
families characterized the CE fraction of cultured neuro-
nal cells and mouse brains. Consistent with the lipid
composition of bovine serum [27,28], C18:1, C20:4,
C18:2, C14:0, C22:6, C18:3, and C16:0 FA families were
detected in the CE fraction of cultured N2a cells. By
contrast, in normal brains only cholesteryl-linoleate was
detected, probably because C18:2 is by far the most
abundant free FA in the standard mouse chow diet [29].
Following Scrapie infection, besides CE 18:2 (52%), a
conspicuous amount of CE 20:4 (48%) was found to
compose cerebral CEs. Since a major pathway for the
production of arachidonic acid (C20:4) is the deacylation
of phospholipids in the sn-2 position by phospholipases
A2 (PLA2) [30], it is possible to speculate that the C20:4
found as an integral component of CE in Scrapie-
infected brains was released from membranes’ phospho-
lipids by the action of PLA2. Actually, prions have
recently been reported to trigger abnormal activation of
the cytoplasmic-PLA2 (c-PLA2) [20,31]. The increased
cholesterol esterification may then represent an attempt
by the infected cell to reduce concentrations of a potent
inflammatory factors’ precursor. Another interesting
result of this study was that high-dose and long-term
oral PRV-treatment of Scrapie-infected C57BL/6 mice,
able to delay disease progression and to prolong survival
times [21], was associated with reduction of cerebral FC
along with a concomitant further increase of the CE
fraction. Intriguingly, in the PRV-treated group, both CE
18:2 (63%) and CE 20:4 (37%) appeared to contribute to
the further increase of CE content in brains. Mechanis-
tic in vivo studies are needed to establish the pathophy-
siological relevance and the dynamic of these changes in
lipid metabolism, especially to define their consequences
in terms of production of inflammatory mediators and
alteration of membrane lipid domains [31,32]. Nonethe-
less, to the best of our knowledge, this may be the first
report that provides evidence of an accumulation of CE
in brains of Scrapie-infected mice. Moreover, we show
an effect of pravastatin on the levels of cerebral CE that
has not been previously reported: a drug-induced ampli-
fication of the esterification of cholesterol in the brain.
These findings could be even more relevant considering
that all, or nearly all, cerebral cholesterol derives from
de novo synthesis, mostly present in the un-esterified
form [33-35]. In addition, the differences found in the
FA composition of CE in neuronal cells and brains, as
well as their different changes after Scrapie infection,
raise the question of whether cultured cells should
represent the model of choice for the comprehension of
the mechanistic link between lipid alterations and the
pathogenesis of prion diseases.
Conclusions
The characterization of cholesterol changes during prion
infection is crucial to the understanding of the mechan-
isms that govern prion generation, and developing of
effective therapies. To date, no univocal hypothesis
exists on either modifications of free vs. esterified cho-
lesterol, or the statins’ cholesterol-lowering effect in
rodent Scrapie. Conflicting and inconclusive data may
be due to different prion models, and the use of dissimi-
lar methods for cholesterol measurements. Our study
advances present knowledge as it: i) reveals the critical
importance of the cholesterol measuring method; ii)
demonstrates that the cholesterol esterification pathway
is enhanced following prion infection; iii) illustrates the
previously unknown promoting effect of pravastatin on
esterification of cerebral cholesterol; iv) shows that the
increased CE fraction in infected brains is due to esteri-
fication of free cholesterol to arachidonic acid, major
precursor of inflammatory mediators; and, v) warns
against the use of cultured cells to unveil the link
between lipids and prions.
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